Articles Accepted

Formulation and Development of bioadhesive pellets for management of Helicobacter pylori infection
by Dr. Munira Momin , 31 Mar 2023
Co-Author(s): Raj Khatri,Sankalp Gharat,Mansi Damani

Helicobacter pylori, a gram-negative bacterium, is group I carcinogen which is responsible for duodenal ulcers, gastric ulcers and gastric cancer. The existing treatment is based on use of proton pump inhibitors but is inadequate owing to factors such as low concentration of antibiotic reaching target site, short residence time and resistance to activity. With a view to mitigate these limitations, we developed bioadhesive pellets of Tinidazole and Pantoprazole sodium sesquihydrate for the management of Helicobacter pylori infection. Tinidazole loaded pellets will act on gastric mucosa and Pantoprazole loaded pellets will act on duodenal mucosa. The readily dispersible bioadhesive pellets are formulated by extrusion spheronization using Noveon and Hydroxypropyl methyl Cellulose (HPMC) as the matrix forming polymers and Microcrystalline cellulose as the core forming agent. The size of placebo pellets was 1.192±0.017mm in size. Pantoprazole pellets were coated with Eudragit S100 to achieve sustained drug release in intestine. In-vitro release studies of pellets showed that 98.331±0.456% and 99.438±0.465% of tinidazole and pantoprazole released by the end of 8 hours. Ex-vivo muco-adhesion study on gastric mucosa of goat demonstrated mucoadhesive force of 2.3544±0.02 N. The study thus concludes that the developed formulation sustains the release of Tinidazole as well as Pantoprazole sodium and provides a better alternative to the current treatment for H. pylori. Thus, use of dual drug loaded bioadhesive drug delivery systems could prove to be efficacious and promising for H. pylori eradication at lower dose, reduced adverse effect and enhanced bioavailability.

Current Issue
December 2023
Quick Contact